Projecting the Impact of the Introduction of SARS-CoV-2 Omicron Variant in China in the Context of Waning Immunity after Vaccination

Hongjie Yu,Jun Cai,Xiaowei Deng,Juan Yang,Kaiyuan Sun,Hengcong Liu,Zhiyuan Chen,Cheng Peng,Xinhua Chen,Qianhui Wu,Junyi Zou,Ruijia Sun,Wen Zheng,Zeyao Zhao,Wanying Lu,Yuxia Liang,Xiaoyu Zhou,Marco Ajelli
DOI: https://doi.org/10.21203/rs.3.rs-1478539/v1
2022-01-01
Abstract:Abstract After the adoption of a dynamic zero-COVID strategy in China for nearly two years, whether and for how long this policy can remain in place is unclear. The debate has thus shifted towards the identification of mitigation strategies capable to prevent the disruption of the healthcare system, should a nationwide epidemic caused by the SARS-CoV-2 Omicron variant start to unfold. To this aim, we developed a mathematical model of SARS-CoV-2 transmission tailored to the unique immunization and epidemiological situation of China. We find that the level of immunity induced by the current vaccination campaign would be insufficient to prevent overwhelming the healthcare system and major losses of human lives. Instead, a synergetic strategy would be needed and based on 1) a heterologous booster vaccination campaign, 2) treating 50% of symptomatic cases with an antiviral with an 80% efficacy in preventing severe outcomes, and 3) the adoption of non-pharmaceutical interventions (NPIs) capable of reducing Rt to ≤2. Protecting vulnerable individuals by ensuring accessibility to vaccines and antivirals, and maintaining a certain degree of NPIs should be emphasised in a future mitigation policy, possibly supported by strengthening critical care capacity and the development of highly efficacious vaccines with long-lasting immunity.
What problem does this paper attempt to address?